Imfinzi (durvalumab)
Drug company: AstraZeneca
844-275-2360
AstraZeneca Access 360 offers 2 financial assistance programs for patients using Imfinzi:
Imfinzi Co-Pay Savings Program
AZ&Me Prescription Savings Program
Lytgobi (futibatinib) Tablets
Drug company: Taiho Oncology
844-824-4648
Taiho Oncology offers 1 financial assistance program for patients using Lytgobi:
Taiho Oncology Patient Support Program
Pemazyre (pemigatinib) Tablets
Drug company: Incyte
855-452-5234
IncyteCARES offers 3 financial assistance programs for patients who have been prescribed Pemazyre:
Pemazyre Savings Program
Pemazyre Patient Assistance Program
Pemazyre Temporary Access Program
Tibsovo (ivosidenib) Tablets
Drug company: Servier Pharmaceuticals
844-409-1141
Servier Pharmaceuticals, through ServierOne, offers 2 financial assistance programs for patients using Tibsovo:
Tibsovo Co-Pay Program
Patient Assistance Program
Table. Drugs Prescribed for Cholangiocarcinoma (Bile Duct Cancer)
- Drug name (generic name)
- Drug company
- Indications
- Patient support services
- Imfinzi (durvalumab)
- AstraZeneca
- Treatment, in combination with gemcitabine and cisplatin, of adults with locally advanced or metastatic BTC
- Imfinzi Co-Pay Savings Program
844-275-2360
AZ&Me Prescription Savings Program
844-275-2360
Drug name (generic name)
Drug company
Indication
Patient support services
- Lytgobi (futibatinib) Tablets
- Taiho Oncology
- Treatment of adults with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions or other rearrangements
- Taiho Oncology
Patient Support
Program
844-824-4648
Drug name (generic name)
Drug company
Indication
Patient support services
- Pemazyre (pemigatinib) Tablets
- Incyte
- Treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma that is associated with an FGFR2 gene fusion or other rearrangements
- Pemazyre Savings
Program
855-452-5234
Pemazyre Patient Assistance Program
855-452-5234
Pemazyre Temporary Access Program
855-452-5234
Drug name (generic name)
Drug company
Indication
Patient support services
- Tibsovo (ivosidenib) Tablets
- Servier Pharmaceuticals
- Treatment of adults with previously treated locally advanced or metastatic cholangiocarcinoma and IDH1 mutation
- Tibsovo Co-Pay Program
844-409-1141
Patient Assistance Program
844-409-1141
Drug name (generic name)
Drug company
Indication
Patient support services